GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics | Recordpub.com - Breaking News, World & Local News, Sports & Multimedia

RecordPub

Tue Feb 16 2010

<a href="http://ox-d.dixcom.com/w/1.0/rc?cs=4df90ef433d93&cb=INSERT_RANDOM_NUMBER_HERE" ><img src="http://ox-d.dixcom.com/w/1.0/ai?auid=23024&cs=4df90ef433d93&cb=INSERT_RANDOM_NUMBER_HERE" border="0" alt=""></a>

GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics

By: 1888PressRelease - Full Feed

Posted on July 22, 2009 at 03:51 AM EDT

GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed worldwide agreements to develop and supply the first point-of-care diagnostic influenza tests to identify specific influenza virus strains using its real-time Polymerase Chain Reaction (PCR) technology platform, the Enigma ML (Mini Laboratory).

Related Stocks:

GlaxoSmithKline PLC ADS

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates

Terms of Service

Copyright Record Publishing Co, LLC. 1995-2010. All Rights Reserved.
Content may not be republished without the expressed written consent of the publisher.

Dix Communications

Website Feedback

Advanced Search

Online Newsroom

About

Citizen Opinion

ClassifiedFinder

Local Businesses